多发性硬化症中的性激素治疗:随机临床试验的系统审查
Monir Shayestehfar1, Mehri Salari2, Shahedeh Karimi3
1Sports Medicine Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Journal of central nervous system disease
|January 8, 2024
概括
性激素疗法在治疗多发性硬化症 (MS),特别是复发性复发性硬化症 (RRMS) 方面表现有前途. 本临床试验和RCT的系统审查综合了当前关于其免疫调节作用的证据.
科学领域:
- 神经免疫学 神经免疫学
- 内分泌学 在内分泌学.
- 临床神经学 临床神经学
背景情况:
- 多发性硬化症 (MS) 表现出对性激素的免疫调节反应,但缺乏全面的系统审查.
- 现有研究强调性激素在MS治疗中的潜在治疗益处.
研究的目的:
- 系统地审查临床试验和随机对照试验 (RCT),评估MS患者的性激素疗法.
- 巩固有关性激素对MS免疫调节和神经退行方面的影响的证据.
主要方法:
- 在PubMed,EMBASE和Scopus数据库中进行全面的文献搜索.
- 包括临床试验和评估性激素对MS患者影响的RCT.
- 数据提取和质量评估使用PEDro规模由独立审查员.
主要成果:
- 九项研究符合系统审查的纳入标准.
- 结果被分为临床,MRI和免疫系统发现.
- 分析的重点是性激素在MS中对免疫调节和神经退行性影响.
结论:
- 性激素疗法对MS的炎症和神经退行性组成部分产生了有前途的效果.
- 这些发现对于复发性复发性多发性硬化症 (RRMS) 患者来说尤其令人鼓舞.
- 需要进一步的研究,以充分阐明性激素在MS治疗中的作用.
更多相关视频
相关概念视频
01:12Hazard Ratio
128
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
128
01:19Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K